Occlusion of Fontan fenestrations using the Amplatzer septal occluder

M Tofeig, K P Walsh, C Chan, E Ladusans, G Gladman, R Arnold

Abstract

Objective—To evaluate the efficacy and safety of the Amplatzer septal occluder device for occlusion of Fontan fenestrations.

Subjects—Five children aged 5–10 years who had undergone a fenestrated Fontan operation.

Setting—Tertiary paediatric cardiology centre.

Methods—Each patient had right and left heart catheterisation to assess haemodynamic suitability for fenestration closure. Sizing of the defect was achieved with a balloon wedge catheter and transoesophageal echocardiography. Transcatheter occlusion of the fenestration was accomplished using a 4 mm device in three patients, and 5 mm or 9 mm devices in the other two patients. Residual shunting following occlusion was assessed using angiography and echocardiography.

Results—100% occlusion rate of the fenestration was achieved in all patients. No complications or device failures were seen during the three month follow up period.

Conclusion—The Amplatzer septal occluder device is safe, and effectively occludes the Fontan fenestration.

(Keywords: Fontan circulation; fenestration occlusion; Amplatzer septal occluder device; congenital heart disease)

A residual communication or fenestration between systemic and pulmonary venous returns is often created during surgical construction of the Fontan circulation. This fenestration may prevent excessive increases in venous pressure in the early postoperative phase, especially in high risk patients. Many of these fenestrations close spontaneously, however some remain open causing persistent arterial desaturation and are a potential cause of paradoxical embolism. Subsequent closure of the fenestration using different transcatheter devices, such as double umbrellas, and coils, has been described. We describe our experience with occlusion of fenestrations using the Amplatzer septal occluder device.

Patients and methods

From February 1997, five children with Fontan circulation (table 1) underwent transcatheter occlusion of an interatrial fenestration with the Amplatzer septal occluder device (AGA Medical Corp, Golden Valley, Minnesota, USA).

OCCCLUSION TECHNIQUE

All procedures were performed under general anaesthesia from the right femoral vein using a 7 F sheath. Arterial pressure was monitored through a small cannula inserted into the left femoral artery. Heparin was given at a dose of 100 IU/kg. Mean right atrial pressure, systemic arterial pressure, and arterial and mixed venous saturations in the Fontan and left sided circulation were measured at baseline, during test occlusion, and after device placement. A 5 F multipurpose catheter was used to cross the fenestration, and a 7 F balloon wedge catheter, passed over an exchange wire, was used to size the fenestration and to assess the effect of occlusion. Transoesophageal echocardiography was used to obtain further measurement of the fenestration, confirm complete balloon occlusion, and monitor deployment of the device. Biplane right atrial angiography was performed before and after deployment of the device.

THE DEVICE

The Amplatzer septal occluder is a self expanding, double saucer shaped device, with a central stent-like connecting cylinder. The device is formed from 720.004" Nitinol wires braided into a cylindrical mesh. Platinum marker bands are applied to the wire ends and

Table 1 Details of five patients requiring occlusion of Fontan fenestrations

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex/age (years)</th>
<th>Weight (kg)</th>
<th>Diagnosis</th>
<th>Type of Fontan</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M/5</td>
<td>13.1</td>
<td>Double inlet left ventricle</td>
<td>Lateral tunnel</td>
</tr>
<tr>
<td>2</td>
<td>F/5.5</td>
<td>15.7</td>
<td>Tricuspid atresia</td>
<td>Lateral tunnel</td>
</tr>
<tr>
<td>3</td>
<td>F/6.5</td>
<td>19.1</td>
<td>Double inlet left ventricle</td>
<td>Lateral tunnel</td>
</tr>
<tr>
<td>4</td>
<td>M/6.5</td>
<td>19.1</td>
<td>Congenitally corrected transposition; pulmonary atresia</td>
<td>Lateral tunnel</td>
</tr>
<tr>
<td>5</td>
<td>F/10</td>
<td>22.5</td>
<td>Tricuspid atresia</td>
<td>Lateral tunnel</td>
</tr>
</tbody>
</table>

Figure 1 The Amplatzer septal occluder device.
laser welded. The shape is then formed by heat treatment. After cooling, a stainless steel sleeve with a female thread is laser welded to one of the marker bands. The defect is closed by the induction of thrombosis, which is accomplished by three polyester patches sewn into the three sections of device. Figure 1 shows the device currently under clinical evaluation with the delivery cable.

Device selection was based on the stretched diameter or known punch diameter used to create the defect. A 6 F or 7 F long sheath and dilator were passed across the defect over the exchange guidewire used for balloon sizing. The dilator and wire were removed and the sheath carefully aspirated. The delivery cable was passed through the loader and the appropriately sized occlusion device was screwed clockwise onto the tip of the delivery cable. The device and the loader were immersed in saline solution and the device was compressed by pulling it into the loader. The loader was introduced into the delivery sheath, and without rotation the device was advanced into the pulmonary venous side of the circulation. The sheath was retracted until the left atrial disc was opened on the pulmonary venous side of the baffle. The sheath and delivery cable were pulled back as one unit until the left atrial disc was snug against the pulmonary venous side of the baffle. While maintaining tension on the delivery cable, the introducing sheath was withdrawn into the Fontan circulation to deploy the tubular frame of the prosthesis in the fenestration and open the right atrial disc in the systemic venous circulation. The position of the occluder was checked with transoesophageal echocardiography before release. Once proper device position was confirmed, the device was released by turning the cable anticlockwise using a pin vise. Haemodynamic measurements and angiography were repeated (fig 2).

Three patients needed 4 mm devices; the other two needed 5 mm or 9 mm devices. Coil embolisation of a residual antegrade pulmonary blood flow was done during the same procedure before fenestration occlusion in one patient.

All patients received 100 IU heparin/kg during the procedure and three doses of prophylactic antibiotics. Heparin was continued overnight if the INR was < 1.8. Patients were discharged home the following day, after chest radiography, echocardiography, and saturations were recorded. These were repeated at one and three months during outpatient visits.

**Results**

All patients tolerated test occlusion and device occlusion of the fenestration without significant changes in arterial or venous pressures. Arterial saturations increased from mean (SD) of 91(1) to 97(0.2)% (p < 0.01; paired t test). The fluoroscopy time ranged between 14 and 45 minutes.

Successful implantation of the occluder device was achieved at the first attempt in all five patients.

The immediate postimplantation angiogram revealed only a small residual leak in patient 2, and a trivial leak in the other four patients. Subsequent follow up echocardiography at one and three months showed complete occlusion in all five patients. Oxygen saturations at one and three months follow up by pulse oximetry ranged from 92–98%.

The position and integrity of the device was satisfactory and there were no complications during the three month follow up period.
Discussion

Transcatheter occlusion of the fenestration following the Fontan procedure can be done safely and effectively using the Amplatzer device. The 100% occlusion rate on follow up echocardiograms in this small group of patients is very encouraging. We experienced no embolisation or misplacement of the device.

The Amplatzer septal occluder was designed for occlusion of left to right shunting fossa ovalis defects, so the device consists of two saucer shaped disks with the left sided disc overlapping the right sided disc. This design appears quite suitable for fenestration closure as the fenestrations are punched in a semicircular shaped Gore-tex patch. The saucer shaped right sided occlusion disc aligns well with the Gore-tex patch, minimising the amount of protrusion into the stagnant Fontan circulation.

Another advantage of this system is that the attachment mechanism consists of a simple screw design, and the device is easily delivered and retrieved through a 6 F or 7 F sheath. The Rashkind double umbrella has also been used to close fenestrations successfully; however, a larger delivery sheath is required or the device can be front-loaded by stripping the delivery catheter off the loading wire.

The use of transoesophageal echocardiography was helpful, although not essential, for ensuring that both discs are correctly placed before release.

In our hospital we do not routinely undertake fenestration closure in the early postoperative phase, but rather reserve it for patients with persistent desaturation from right to left shunting through the fenestration for more than one to two years after the Fontan operation. In these five patients transcatheter occlusion of Fontan fenestrations was performed because of persistent desaturation for more than one year after the surgical construction of the circulation. In one patient there had also been an episode of cerebral thromboembolism, which we ascribed to thrombus passage through the fenestration. Occlusion of the fenestrations appeared to cause no adverse haemodynamic effects; the central venous pressure was not significantly increased and there was no undue systemic venous desaturation. However, all these measurements were taken under general anaesthesia and do not necessarily reflect the capacity to increase cardiac output during exercise. So far all patients and/or parents report symptomatic improvement, although this may be related to the parents’ perceptions of lack of visible cyanosis.